{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:31:33Z","timestamp":1788305493971,"version":"build-2803163510"},"reference-count":63,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Autoimmune manifestations are increasingly being recognized as a component of several forms of primary immunodeficiencies (PID). Defects in purging of self-reactive T and B cells, impaired Fas-mediated apoptosis, abnormalities in development and\/or function of regulatory T cells, and persistence of immune activation as a result of inability to clear infections have been shown to account for this association. Among autoimmune manifestations in patients with PID, cytopenias are particularly common. Up to 80% of patients with autoimmune lymphoproliferative syndrome (ALPS) have autoantibodies, and autoimmune hemolytic anemia and immune thrombocytopenia have been reported in 23% and 51% of ALPS patients, and may even mark the onset of the disease. ALPS-associated cytopenias are often refractory to conventional treatment and represent a therapeutic challenge. Autoimmune manifestations occur in 22% to 48% of patients with common variable immunodeficiencies (CVIDs), and are more frequent among CVID patients with splenomegaly and granulomatous disease. Finally, autoimmune cytopenias have been reported also in patients with combined immunodeficiency. In particular, autoimmune hemolytic anemia is very common among infants with nucleoside phosphorylase deficiency. While immune suppression may be beneficial in these cases, full resolution of the autoimmune manifestations ultimately depends on immune reconstitution, which is typically provided by hematopoietic cell transplantation.<\/jats:p>","DOI":"10.1182\/asheducation-2009.1.139","type":"journal-article","created":{"date-parts":[[2009,12,11]],"date-time":"2009-12-11T15:35:31Z","timestamp":1260545731000},"page":"139-143","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":55,"title":["Primary immunodeficiencies (PIDs) presenting with cytopenias"],"prefix":"10.1182","volume":"2009","author":[{"given":"Luigi D.","family":"Notarangelo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111702230819700_R1","doi-asserted-by":"crossref","unstructured":"Carneiro-Sampaio M, Coutinho A. Tolerance and autoimmunity: lessons at the bedside of primary immunodeficiencies. Adv Immunol. 2007;95:51\u201382.","DOI":"10.1016\/S0065-2776(07)95002-6"},{"key":"2019111702230819700_R2","doi-asserted-by":"crossref","unstructured":"Bussone G, Mouthon L. Autoimmune manifestations in primary immune deficiencies. Autoimmun Rev. 2009;8:332\u2013336.","DOI":"10.1016\/j.autrev.2008.11.004"},{"key":"2019111702230819700_R3","doi-asserted-by":"crossref","unstructured":"Liston A, Enders A, Siggs OM. Unravelling the association of partial T-cell immunodeficiency and immune dysregulation. Nat Rev Immunol. 2008;8:545\u2013558.","DOI":"10.1038\/nri2336"},{"key":"2019111702230819700_R4","doi-asserted-by":"crossref","unstructured":"Oliveira JB, Gupta S. Disorders of apoptosis: mechanisms for autoimmunity in primary immunodeficiency diseases. J Clin Immunol. 2008;28:S20\u2013S28.","DOI":"10.1007\/s10875-007-9161-4"},{"key":"2019111702230819700_R5","doi-asserted-by":"crossref","unstructured":"Westerberg LS, Klein C, Snapper SB. Breakdown of T cell tolerance and autoimmunity in primary immunodeficiency--lessons learned from monogenic disorders in mice and men. Curr Opin Immunol. 2008;20:646\u2013654.","DOI":"10.1016\/j.coi.2008.10.004"},{"key":"2019111702230819700_R6","doi-asserted-by":"crossref","unstructured":"Goyal R, Bulua AC, Nikolov NP, Schwartzberg PL, Siegel RM. Rheumatologic and autoimmune manifestations of primary immunodeficiency disorders. Curr Opin Rheumatol. 2009;21:78\u201384.","DOI":"10.1097\/BOR.0b013e32831cb939"},{"key":"2019111702230819700_R7","doi-asserted-by":"crossref","unstructured":"Bosticardo M, Marangoni F, Aiuti A, Villa A, Roncarolo MG. Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome. Blood. 2009;113:6288\u20136295.","DOI":"10.1182\/blood-2008-12-115253"},{"key":"2019111702230819700_R8","doi-asserted-by":"crossref","unstructured":"Schurman SH, Candotti F. Autoimmunity in Wiskott-Aldrich syndrome. Curr Opin Rheumatol. 2003;15:446\u2013453.","DOI":"10.1097\/00002281-200307000-00012"},{"key":"2019111702230819700_R9","doi-asserted-by":"crossref","unstructured":"Dupuis-Girod S, Medioni J, Haddad E, et al. Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients. Pediatrics. 2003;111:e622\u2013e627.","DOI":"10.1542\/peds.111.5.e622"},{"key":"2019111702230819700_R10","doi-asserted-by":"crossref","unstructured":"Durandy A, Revy P, Imai K, Fischer A. Hyper-immunoglobulin M syndromes caused by intrinsic B-lymphocyte defects. Immunol Rev. 2005;203:67\u201379.","DOI":"10.1111\/j.0105-2896.2005.00222.x"},{"key":"2019111702230819700_R11","doi-asserted-by":"crossref","unstructured":"Jesus AA, Duarte AJ, Oliveira JB. Autoimmunity in hyper-IgM syndrome. J Clin Immunol. 2008;28:S62\u2013S66.","DOI":"10.1007\/s10875-008-9171-x"},{"key":"2019111702230819700_R12","doi-asserted-by":"crossref","unstructured":"Su HC, Lenardo MJ. Genetic defects of apoptosis and primary immunodeficiency. Immunol Allergy Clin North Am. 2008;28:329\u2013351.","DOI":"10.1016\/j.iac.2008.01.002"},{"key":"2019111702230819700_R13","doi-asserted-by":"crossref","unstructured":"Rieux-Laucat F, Le Deist F, Hivroz C, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science. 1995;268:1347\u20131349.","DOI":"10.1126\/science.7539157"},{"key":"2019111702230819700_R14","doi-asserted-by":"crossref","unstructured":"Del-Rey M, Ruiz-Contreras J, Bosque A, et al. A homozygous Fas ligand gene mutation in a patient causes a new type of autoimmune lymphoproliferative syndrome. Blood. 2006;108:1306\u20131312.","DOI":"10.1182\/blood-2006-04-015776"},{"key":"2019111702230819700_R15","doi-asserted-by":"crossref","unstructured":"Chun HJ, Zheng L, Ahmad M, et al. Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature. 2002;419:395\u2013399.","DOI":"10.1038\/nature01063"},{"key":"2019111702230819700_R16","doi-asserted-by":"crossref","unstructured":"Wang J, Zheng L, Lobito A, et al. Inherited human caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell. 1999;98:47\u201358.","DOI":"10.1016\/S0092-8674(00)80605-4"},{"key":"2019111702230819700_R17","doi-asserted-by":"crossref","unstructured":"Holzelova E, Vonarbourg C, Stolzenberg MC, et al. Autoimmune lymphoproliferative syndrome with somatic Fas mutations. N Engl J Med. 2004;351:1409\u20131418.","DOI":"10.1056\/NEJMoa040036"},{"key":"2019111702230819700_R18","doi-asserted-by":"crossref","unstructured":"Dianzani U, Bragardo M, DiFranco D, et al. Deficiency of the Fas apoptosis pathway without Fas gene mutations in pediatric patients with autoimmunity\/lymphoproliferation. Blood. 1997;89:2871\u20132879.","DOI":"10.1182\/blood.V89.8.2871"},{"key":"2019111702230819700_R19","doi-asserted-by":"crossref","unstructured":"Oliveira JB, Bide\u0300re N, Niemela JE, et al. NRAS mutation causes a human autoimmune lymphoproliferative syndrome. Proc Natl Acad Sci U S A. 2007;104:8953\u20138958.","DOI":"10.1073\/pnas.0702975104"},{"key":"2019111702230819700_R20","doi-asserted-by":"crossref","unstructured":"Rischewski JR, Ku\u0308hne T, Imbach P, Ehl S. Evans syndrome and idiopathic thrombocytopenic purpura in families: consider autoimmune lymphoproliferative disease. Pediatr Blood Cancer. 2008;50:1295\u20131296.","DOI":"10.1002\/pbc.21501"},{"key":"2019111702230819700_R21","doi-asserted-by":"crossref","unstructured":"Worth A, Thrasher AJ, Gaspar HB. Autoimmune lymphoproliferative syndrome: molecular basis of disease and clinical phenotype. Br J Haematol. 2006;133:124\u201340.","DOI":"10.1111\/j.1365-2141.2006.05993.x"},{"key":"2019111702230819700_R22","doi-asserted-by":"crossref","unstructured":"Bristeau-Leprince A, Mateo V, Lim A, et al. Human TCR alpha\/beta+ CD4-CD8- double-negative T cells in patients with autoimmune lymphoproliferative syndrome express restricted Vbeta TCR diversity and are clonally related to CD8+ T cells. J Immunol. 2008;181:440\u2013448.","DOI":"10.4049\/jimmunol.181.1.440"},{"key":"2019111702230819700_R23","doi-asserted-by":"crossref","unstructured":"Magerus-Chatinet A, Stolzenberg MC, Loffredo MS, et al. FAS-L, IL-10, and double-negative CD4- CD8- TCR alpha\/beta+ T cells are reliable markers of autoimmune lymphoproliferative syndrome (ALPS) associated with FAS loss of function. Blood. 2009;113:3027\u20133030.","DOI":"10.1182\/blood-2008-09-179630"},{"key":"2019111702230819700_R24","doi-asserted-by":"crossref","unstructured":"Sneller MC, Dale JK, Straus SE. Autoimmune lymphoproliferative syndrome. Curr Opin Rheumatol. 2003;15:417\u2013421.","DOI":"10.1097\/00002281-200307000-00008"},{"key":"2019111702230819700_R25","doi-asserted-by":"crossref","unstructured":"Kwon SW, Procter J, Dale JK, Straus SE, Stroncek DF. Neutrophil and platelet antibodies in autoimmune lymphoproliferative syndrome. Vox Sang. 2003;85:307\u2013312.","DOI":"10.1111\/j.0042-9007.2003.00374.x"},{"key":"2019111702230819700_R26","doi-asserted-by":"crossref","unstructured":"Fleisher TA. The autoimmune lymphoproliferative syndrome: an experiment of nature involving lymphocyte apoptosis. Immunol Res. 2008;40:87\u201392.","DOI":"10.1007\/s12026-007-8001-1"},{"key":"2019111702230819700_R27","doi-asserted-by":"crossref","unstructured":"Rieux-Laucat F, Le Deist F, Fischer A. Autoimmune lymphoproliferative syndromes: genetic defects of apoptosis pathways. Cell Death Differ. 2003;10:124\u2013133.","DOI":"10.1038\/sj.cdd.4401190"},{"key":"2019111702230819700_R28","doi-asserted-by":"crossref","unstructured":"Teachey DT, Manno CS, Axsom KM, et al. Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS). Blood. 2005;105:2443\u20132448.","DOI":"10.1182\/blood-2004-09-3542"},{"key":"2019111702230819700_R29","doi-asserted-by":"crossref","unstructured":"Teachey DT, Greiner R, Seif A, et al. Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. Br J Haematol. 2009;145:101\u2013106.","DOI":"10.1111\/j.1365-2141.2009.07595.x"},{"key":"2019111702230819700_R30","doi-asserted-by":"crossref","unstructured":"Rao VK, Price S, Perkins K, et al. Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS). Pediatr Blood Cancer. 2009;52:847\u2013852.","DOI":"10.1002\/pbc.21965"},{"key":"2019111702230819700_R31","doi-asserted-by":"crossref","unstructured":"Chapel H, Cunningham-Rundles C. Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions. Br J Haematol. 2009;145:709\u2013727.","DOI":"10.1111\/j.1365-2141.2009.07669.x"},{"key":"2019111702230819700_R32","doi-asserted-by":"crossref","unstructured":"Chapel H, Lucas M, Lee M, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood. 2008;112:277\u2013286.","DOI":"10.1182\/blood-2007-11-124545"},{"key":"2019111702230819700_R33","doi-asserted-by":"crossref","unstructured":"Brandt D, Gershwin ME. Common variable immune deficiency and autoimmunity. Autoimmun Rev. 2006;5:465\u2013470.","DOI":"10.1016\/j.autrev.2006.03.010"},{"key":"2019111702230819700_R34","doi-asserted-by":"crossref","unstructured":"Knight AK, Cunningham-Rundles C. Inflammatory and autoimmune complications of common variable immune deficiency. Autoimmun Rev. 2006;5:156\u2013169.","DOI":"10.1016\/j.autrev.2005.10.002"},{"key":"2019111702230819700_R35","doi-asserted-by":"crossref","unstructured":"Cunningham-Rundles C. Autoimmune manifestations in common variable immunodeficiency. J Clin Immunol. 2008;28:S42\u2013S45.","DOI":"10.1007\/s10875-008-9182-7"},{"key":"2019111702230819700_R36","doi-asserted-by":"crossref","unstructured":"Lopes-da-Silva S, Rizzo LV. Autoimmunity in common variable immunodeficiency. J Clin Immunol. 2008;28:S46\u2013S55.","DOI":"10.1007\/s10875-008-9172-9"},{"key":"2019111702230819700_R37","doi-asserted-by":"crossref","unstructured":"Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol. 1999;92:34\u201348.","DOI":"10.1006\/clim.1999.4725"},{"key":"2019111702230819700_R38","doi-asserted-by":"crossref","unstructured":"Quinti I, Soresina A, Spadaro G, et al; Italian Primary Immunodeficiency Network. Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency. J Clin Immunol. 2007;27:308\u2013316.","DOI":"10.1007\/s10875-007-9075-1"},{"key":"2019111702230819700_R39","doi-asserted-by":"crossref","unstructured":"Michel M, Chanet V, Galicier L, et al. Autoimmune thrombocytopenic purpura and common variable immunodeficiency: analysis of 21 cases and review of the literature. Medicine. 2004;83:254\u2013263.","DOI":"10.1097\/01.md.0000133624.65946.40"},{"key":"2019111702230819700_R40","doi-asserted-by":"crossref","unstructured":"Genre J, Errante PR, Kokron CM, Toledo-Barros M, Ca\u0302mara NO, Rizzo LV. Reduced frequency of CD4(+)CD25(HIGH)FOXP3(+) cells and diminished FOXP3 expression in patients with common variable immunodeficiency: a link to autoimmunity?. Clin Immunol. 2009;132:215\u2013221.","DOI":"10.1016\/j.clim.2009.03.519"},{"key":"2019111702230819700_R41","doi-asserted-by":"crossref","unstructured":"Fevang B, Yndestad A, Sandberg WJ, et al. Low numbers of regulatory T cells in common variable immunodeficiency: association with chronic inflammation in vivo. Clin Exp Immunol. 2007;147:521\u2013525.","DOI":"10.1111\/j.1365-2249.2006.03314.x"},{"key":"2019111702230819700_R42","doi-asserted-by":"crossref","unstructured":"Warnatz K, Wehr C, Dra\u0308ger R, et al. Expansion of CD19(hi)CD21(lo\/neg) B cells in common variable immunodeficiency (CVID) patients with autoimmune cytopenia. Immunobiology. 2002;206:502\u2013513.","DOI":"10.1078\/0171-2985-00198"},{"key":"2019111702230819700_R43","doi-asserted-by":"crossref","unstructured":"Zhang L, Radigan L, Salzer U, et al. Transmembrane activator and calcium-modulating cyclophilin ligand interactor mutations in common variable immunodeficiency: clinical and immunologic outcomes in heterozygotes. J Allergy Clin Immunol. 2007;120:1178\u20131185.","DOI":"10.1016\/j.jaci.2007.10.001"},{"key":"2019111702230819700_R44","doi-asserted-by":"crossref","unstructured":"Knight AK, Radigan L, Marron T, Langs A, Zhang L, Cunningham-Rundles C. High serum levels of BAFF, APRIL, and TACI in common variable immunodeficiency. Clin Immunol. 2007;124:182\u2013189.","DOI":"10.1016\/j.clim.2007.04.012"},{"key":"2019111702230819700_R45","doi-asserted-by":"crossref","unstructured":"Milner JD, Fasth A, Etzioni A. Autoimmunity in severe combined immunodeficiency (SCID): lessons from patients and experimental models. J Clin Immunol. 2008;28:S29\u2013S33.","DOI":"10.1007\/s10875-007-9159-y"},{"key":"2019111702230819700_R46","doi-asserted-by":"crossref","unstructured":"Villa A, Notarangelo LD, Roifman CM. Omenn syndrome: inflammation in leaky severe combined immunodeficiency. J Allergy Clin Immunol. 2008;122:1082\u20131086.","DOI":"10.1016\/j.jaci.2008.09.037"},{"key":"2019111702230819700_R47","doi-asserted-by":"crossref","unstructured":"Poliani PL, Facchetti F, Ravanini M, et al. Early defects in human T-cell development severely affect distribution and maturation of thymic stromal cells: possible implications for the pathophysiology of Omenn syndrome. Blood. 2009;114:105\u2013108.","DOI":"10.1182\/blood-2009-03-211029"},{"key":"2019111702230819700_R48","doi-asserted-by":"crossref","unstructured":"Hillion S, Rochas C, Youinou P, Jamin C. Expression and reexpression of recombination activating genes: relevance to the development of autoimmune states. Ann N Y Acad Sci. 2005;1050:10\u201318.","DOI":"10.1196\/annals.1313.002"},{"key":"2019111702230819700_R49","doi-asserted-by":"crossref","unstructured":"Cohen A, Doyle D, Martin DW Jr, Ammann AJ. Abnormal purine metabolism and purine overproduction in a patient deficient in purine nucleoside phosphorylase. N Engl J Med. 1976;295:1449\u20131454.","DOI":"10.1056\/NEJM197612232952603"},{"key":"2019111702230819700_R50","doi-asserted-by":"crossref","unstructured":"Carapella-de Luca E, Aiuti F, Lucarelli P, et al. A patient with nucleoside phosphorylase deficiency, selective T-cell deficiency, and autoimmune hemolytic anemia. J Pediatr. 1978;93:1000\u20131003.","DOI":"10.1016\/S0022-3476(78)81237-2"},{"key":"2019111702230819700_R51","unstructured":"Markert ML. Purine nucleoside phosphorylase deficiency. Immunodefic Rev. 1991;3:45\u201381."},{"key":"2019111702230819700_R52","doi-asserted-by":"crossref","unstructured":"Rich KC, Arnold WJ, Palella T, Fox IH. Cellular immune deficiency with autoimmune hemolytic anemia in purine nucleoside phosphorylase deficiency. Am J Med. 1979;67:172\u2013176.","DOI":"10.1016\/0002-9343(79)90100-1"},{"key":"2019111702230819700_R53","doi-asserted-by":"crossref","unstructured":"Ozsahin H, Arredondo-Vega FX, Santisteban I, et al. Adenosine deaminase deficiency in adults. Blood. 1997;89:2849\u20132855.","DOI":"10.1182\/blood.V89.8.2849"},{"key":"2019111702230819700_R54","doi-asserted-by":"crossref","unstructured":"Shovlin CL, Hughes JM, Simmonds HA, et al. Adult presentation of adenosine deaminase deficiency. Lancet. 1993;341:1471.","DOI":"10.1016\/0140-6736(93)90910-9"},{"key":"2019111702230819700_R55","doi-asserted-by":"crossref","unstructured":"Levy A, Michel G, Lemerrer M, Philip N. Idiopathic thrombocytopenic purpura in two mothers of children with DiGeorge sequence: a new component manifestation of deletion 22q11? Am J Med Genet. 1997;69:356\u2013359.","DOI":"10.1002\/(SICI)1096-8628(19970414)69:4<356::AID-AJMG4>3.0.CO;2-J"},{"key":"2019111702230819700_R56","doi-asserted-by":"crossref","unstructured":"DePiero AD, Lourie EM, Berman BW, Robin NH, Zinn AB, Hostoffer RW. Recurrent immune cytopenias in two patients with DiGeorge\/velocardiofacial syndrome. J Pediatr. 1997;131:484\u2013486.","DOI":"10.1016\/S0022-3476(97)80085-6"},{"key":"2019111702230819700_R57","doi-asserted-by":"crossref","unstructured":"Markert ML, Devlin BH, Alexieff MJ, et al. Review of 54 patients with complete DiGeorge anomaly enrolled in protocols for thymus transplantation: outcome of 44 consecutive transplants. Blood. 2007;109:4539\u20134547.","DOI":"10.1182\/blood-2006-10-048652"},{"key":"2019111702230819700_R58","doi-asserted-by":"crossref","unstructured":"de Villartay JP, Lim A, Al-Mousa H, et al. A novel immunodeficiency associated with hypomorphic RAG1 mutations and CMV infection. J Clin Invest. 2005;115:3291\u20133299.","DOI":"10.1172\/JCI25178"},{"key":"2019111702230819700_R59","doi-asserted-by":"crossref","unstructured":"Ehl S, Schwarz K, Enders A, et al. A variant of SCID with specific immune responses and predominance of gamma delta T cells. J Clin Invest. 2005;115:3140\u20133148.","DOI":"10.1172\/JCI25221"},{"key":"2019111702230819700_R60","doi-asserted-by":"crossref","unstructured":"Pasic S, Djuricic S, Ristic G, Slavkovic B. Recombinase-activating gene 1 immunodeficiency: different immunological phenotypes in three siblings. Acta Paediatr. 2009;98:1062\u20131064.","DOI":"10.1111\/j.1651-2227.2009.01250.x"},{"key":"2019111702230819700_R61","doi-asserted-by":"crossref","unstructured":"Ege M, Ma Y, Manfras B, et al. Omenn syndrome due to ARTEMIS mutations. Blood. 2005;105:4179\u20134186.","DOI":"10.1182\/blood-2004-12-4861"},{"key":"2019111702230819700_R62","doi-asserted-by":"crossref","unstructured":"Buck D, Malivert L, de Chasseval R, et al. Cernunnos, a novel nonhomologous end-joining factor, is mutated in human immunodeficiency with microcephaly. Cell. 2006;124:287\u2013299.","DOI":"10.1016\/j.cell.2005.12.030"},{"key":"2019111702230819700_R63","doi-asserted-by":"crossref","unstructured":"Enders A, Fisch P, Schwarz K, et al. A severe form of human combined immunodeficiency due to mutations in DNA ligase IV. J Immunol. 2006;176:5060\u20135068.","DOI":"10.4049\/jimmunol.176.8.5060"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2009\/1\/139\/645362\/139_143ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2009\/1\/139\/645362\/139_143ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T02:23:28Z","timestamp":1573957408000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2009\/1\/139\/19770\/Primary-immunodeficiencies-PIDs-presenting-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,1]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2009.1.139","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,1]]}}}